STOCK TITAN

Spero Therapeuti - SPRO STOCK NEWS

Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.

Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.

Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.

All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced 15 data presentations at IDWeek™ 2020, taking place virtually from October 21-25, 2020. Key topics include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial for tebipenem HBr, which showed non-inferiority to IV ertapenem for treating complicated urinary tract infections (cUTI). Other presentations cover Spero's pipeline products, including SPR720 and SPR206. The company aims to advance antibacterials targeting multi-drug resistant infections and plans to submit a New Drug Application for tebipenem HBr in Q2 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
-
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced a key opinion leader call on September 30, 2020, to discuss oral tebipenem HBr for complicated urinary tract infections (cUTI). Dr. Keith Kaye will present on the treatment landscape and unmet needs. The call follows positive top-line results from Spero’s ADAPT-PO Phase 3 trial, where tebipenem HBr was shown to be statistically non-inferior to intravenous ertapenem. If approved, tebipenem HBr would be the first oral carbapenem approved in the U.S., with an NDA submission expected in Q2 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced key investor presentations for September 2020, led by CEO Ankit Mahadevia. The company focuses on developing treatments for multi-drug resistant infections and rare diseases. Spero will present at the Cantor Virtual Global Healthcare Conference on September 17 and the Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit on September 23. Webcasts will be available on their website. Notably, Spero reported positive Phase 3 ADAPT-PO trial results for its lead product, tebipenem HBr, aimed at treating complicated urinary tract infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences
Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) has priced its public offering of 4,785,000 shares of common stock and 3,215,000 shares of non-voting Series D Convertible Preferred Stock at $10.00 each, aiming for gross proceeds of $80.0 million. The offering, closing around September 15, 2020, includes a 30-day option for underwriters to purchase an additional 1,200,000 shares. Proceeds will fund the development of tebipenem HBr and support general corporate purposes. The offering complies with an SEC Form S-3 registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.88%
Tags
none
-
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced a public offering of 8,000,000 shares of common stock, including shares of non-voting Series D Convertible Preferred Stock convertible into 1,000 shares of common stock. The net proceeds will fund the advancement of its product tebipenem HBr, aimed at filing a New Drug Application with the FDA, ongoing pipeline development, and general corporate purposes. The offering is subject to market conditions, with underwriters granted a 30-day option to purchase an additional 15% of shares at the public offering price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.09%
Tags
-
Rhea-AI Summary

Spero Therapeutics announced positive topline results from its pivotal Phase 3 trial of oral tebipenem HBr, indicating statistical non-inferiority to intravenous ertapenem for treating complicated urinary tract infections (cUTI) and acute pyelonephritis. The trial included 1,372 patients and demonstrated overall response rates of 58.8% for tebipenem HBr compared to 61.6% for ertapenem. Tebipenem HBr had a comparable safety profile, with treatment-emergent adverse events reported in about 26% of patients. Spero plans to submit a NDA to the FDA in Q2 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.87%
Tags
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) announced the FDA's acceptance of its Investigational New Drug application for SPR720, an oral antimicrobial targeting nontuberculous mycobacterial (NTM) pulmonary disease. This acceptance allows Spero to initiate a Phase 2a trial by the end of 2020, involving around 90 patients. SPR720 aims to fulfill a critical unmet need for NTM infections, as it is the first oral antibiotic being developed specifically for this condition. It also has QIDP and orphan drug designations from the FDA, enhancing its development prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
none
-
Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on July 31, 2020, that its Compensation Committee granted non-qualified stock options to purchase 22,000 shares to two new employees, as part of the 2019 Inducement Equity Incentive Plan. The options have an exercise price of $11.70 per share, equal to the closing stock price on that date, vesting over four years. This plan is designed to attract talent by offering inducements for new hires who have not previously been employed by Spero.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.58%
Tags
none
-
Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on June 30, 2020, the granting of non-qualified stock options for 40,000 shares to five new employees under its 2019 Inducement Equity Incentive Plan. The options, with an exercise price of $13.53 per share, will vest over four years, with 25% vesting after the first year. This incentive is in accordance with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting talent in the biopharmaceutical sector focused on treating multi-drug resistant bacterial infections and rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
none
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) will present a corporate update at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020, at 9:00 a.m. ET. The presentation will be led by Ankit Mahadevia, M.D., President and CEO. Interested individuals can access the webcast on Spero's website under the 'Events and Presentations' section. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases, including its lead product candidate, tebipenem HBr, aimed at treating MDR Gram-negative infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.64%
Tags
conferences

FAQ

What is the current stock price of Spero Therapeuti (SPRO)?

The current stock price of Spero Therapeuti (SPRO) is $0.71 as of April 28, 2025.

What is the market cap of Spero Therapeuti (SPRO)?

The market cap of Spero Therapeuti (SPRO) is approximately 40.5M.
Spero Therapeuti

Nasdaq:SPRO

SPRO Rankings

SPRO Stock Data

40.53M
41.52M
24.47%
24.89%
0.78%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE